Immunopotentiation with Ubenimex for prevention of leukemia relapse after allogeneic BMT. The Study Group of Ubenimex for BMT
Hiraoka, A.; Shibata, H.; Masaoka, T.
Transplantation Proceedings 24(6): 3047-3048
1992
ISSN/ISBN: 0041-1345 PMID: 1466051 Document Number: 388068
Document emailed within 1 workday
Related Documents
Ueda, T.; Tohyama, K.; Wano, Y.; Tsutani, H.; Fukushima, T.; Iwasaki, H.; Urasaki, Y.; Gotoh, N.; Kimura, S.; Okumura, E. 1994: Pharmacokinetic and clinical pilot study of high-dose intermittent ubenimex treatment in patients with myelodysplastic syndrome Anticancer Research 14(5b): 2093-2097Schmid, H.; von Schenck, U.; Hartmann, R.; Borgmann, A.; Henze, G. 1996: Allogeneic BMT vs. chemotherapy in late bone marrow relapsed childhood non-T/non-B ALL: results of BFM ALL relapse studies. BFM Relapse Study Group Bone Marrow Transplantation 18(Suppl 2): 28-30
Zapatero, A.; Martín de Vidales, C.; Pinar, B.; Rodríguez, F.; Marín, A.; Cerezo, L.; Domínguez, P.; Pérez Torrubia, A. 1996: Prognostic factors affecting leukemia relapse after allogeneic BMT conditioned with cyclophosphamide and fractionated TBi Bone Marrow Transplantation 18(3): 591-596
Abshire, T.C.; Buchanan, G.R.; Jackson, J.F.; Shuster, J.J.; Brock, B.; Head, D.; Behm, F.; Crist, W.M.; Link, M.; Borowitz, M. 1992: Morphologic, immunologic and cytogenetic studies in children with acute lymphoblastic leukemia at diagnosis and relapse: a Pediatric Oncology Group study Leukemia 6(5): 357-362
Zwaan, F.E.; Hermans, J. 1990: Acute lymphoblastic leukemia; factors influencing relapse after allogeneic bone marrow transplantation Bone Marrow Transplantation 6(Suppl 1): 71
Barrios, M.; Jiménez-Velasco, A.; Román-Gómez, Jé.; Madrigal, Mía.Elena.; Castillejo, J.Antonio.; Torres, A.; Heiniger, A. 2003: Chimerism status is a useful predictor of relapse after allogeneic stem cell transplantation for acute leukemia Haematologica 88(7): 801-810
Spinelli, O.; Giussani, U.; Borleri, G.; Lazzari, M.; Michelato, A.; Dotti, G.; Barbui, T.; Rambaldi, A. 2000: Need for an accurate molecular diagnosis to assess the donor origin of leukemia relapse after allogeneic stem cell transplantation Haematologica 85(11): 1153-1157
Kodera, Y.; Yamada, H.; Morishima, Y.; Ohno, R.; Yoshikawa, S.; Yamada, K. 1986: Influence of pretransplant clinical conditions on the prognosis of patients treated with allogeneic bone marrow transplantation during leukemia relapse Nihon Ketsueki Gakkai Zasshi: Journal of Japan Haematological Society 49(1): 86-92
Porter, D.L.; Roth, M.S.; Lee, S.J.; McGarigle, C.; Ferrara, J.L.; Antin, J.H. 1996: Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation Bone Marrow Transplantation 18(5): 975-980
Zittoun, R.; Mandelli, F.; Willemze, R.; de Witte, T.; Tura, S.; Ferrini, P.R.; Stryckmans, P.; Gattringer, C.; Petti, M.C.; Solbu, G. 1992: Allogeneic versus autologous bone marrow transplantation (BMT) versus intensive consolidation in acute myelogenous leukemia (AML) in first remission. An EORTC-Gimema phase IIi trial (AML8 A). the EORTC Leukemia Cooperative Group and the GIMEMA Group Leukemia 6(Suppl 2): 114-115
Sanders, J.E.; Buckner, C.D.; Clift, R.A.; Fefer, A.; McGuffin, R.; Storb, R.; Appelbaum, F.; Bensinger, W.; Beatty, P.; Doney, K. 1988: Second marrow transplants in patients with leukemia who relapse after allogeneic marrow transplantation Bone Marrow Transplantation 3(1): 11-19
Sanders, J.E.; Buckner, C.D.; Clift, R.A.; Fefer, A.; McGuffin, R.; Storb, R.; Appelbaum, F.; Bensinger, W.; Beatty, P.; Doney, K. 1988: Second marrow transplants in patients with leukemia who relapse after allogeneic marrow transplantation Bone Marrow Transplantation 3(1): 11-19
Mengarelli, A.; Iori, A.Paola.; Cerretti, R.; Cerilli, L.; Romano, A.; Arcese, W. 2002: Increasing risk of relapse after allogeneic stem cell transplant for adult acute lymphoblastic leukemia in > or = 2nd complete remission induced by highly intensive chemotherapy Haematologica 87(7): 782-784
Moussalem, M.; Esperou Bourdeau, H.; Devergie, A.; Baruchel, A.; Ribaud, P.; Socie, G.; Parquet, N.; Traineau, R.; Hirsch, I.; Schaison, G. 1995: Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission: factors predictive of survival, relapse and graft-versus-host disease Bone Marrow Transplantation 15(6): 943-947
Ringdén, O.; Labopin, M.; Gluckman, E.; Reiffers, J.; Vernant, J.P.; Jouet, J.P.; Harrousseau, J.L.; Fiere, D.; Bacigalupo, A.; Frassoni, F.; Gorin, N.C. 1996: Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin a combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation Bone Marrow Transplantation 18(5): 921-929
Takami, A.; Chuhjo, T.; Nakao, S. 2002: Relapse of chronic myeloid leukemia (CML) in lymphoid crisis after allogeneic bone marrow transplantation for CML in chronic phase with busulfan plus cyclophosphamide regimen Haematologica 87(6): 659-661
Zikos, P.; Van Lint, M.T.; Lamparelli, T.; Gualandi, F.; Occhini, D.; Bregante, S.; Berisso, G.; Mordini, N.; Incagliato, M.; Fugazza, G.; Sessarego, M.; Bacigalupo, A. 1998: Allogeneic hemopoietic stem cell transplantation for patients with high risk acute lymphoblastic leukemia: favorable impact of chronic graft-versus-host disease on survival and relapse Haematologica 83(10): 896-903
Johann, M.; Bobbe, G.; Franke, E.; Wodarz, N. 2003: Relapse prevention group for alcohol dependent patients Psychiatrische Praxis 30 Suppl. 2: S125-S128
Sievers, E.L.; Lange, B.J.; Sondel, P.M.; Krailo, M.D.; Gan, J.; Tjoa, T.; Liu-Mares, W.; Feig, S.A. 2000: Children's cancer group trials of interleukin-2 therapy to prevent relapse of acute myelogenous leukemia Cancer Journal from Scientific American 6(Suppl): S39-S44
Pession, A.; Locatelli, F.; Zecca, M.; Rondelli, R.; Prete, A.; Bonetti, F.; Paolucci, G. 1998: Cyclosporine-A as GVHD prophylaxis in allogeneic BMT for childhood acute leukemia. AIEOP-BMT group Bone Marrow Transplantation 21(Suppl 2): S50-S52